Fezagepras
Fezagepras (Setogepram) acts as an orally active agonist for GPR40 and as an antagonist or inverse agonist for GPR84[1]. Fezagepras decreases renal, liver and pancreatic fibrosis[1][2]. Fezagepras exerts anti-fibrotic, anti-inflammatory and anti-proliferative actions[2].
Product Specifications
CAS Number
1002101-19-0
Product Name Alternative
Setogepram; PBI-4050
UNSPSC
12352005
Hazard Statement
H302, H312, H332
Target
Free Fatty Acid Receptor; GPR84
Type
Reference compound
Related Pathways
GPCR/G Protein
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/setogepram.html
Purity
99.38
Solubility
DMSO : 60 mg/mL (ultrasonic; warming)
Smiles
O=C(CC1=CC=CC(CCCCC)=C1)O
Molecular Formula
C13H18O2
Molecular Weight
206.28
Precautions
H302, H312, H332
References & Citations
[1]Li Y, et al. Fatty acid receptor modulator PBI-4050 inhibits kidney fibrosis and improves glycemic control. JCI Insight. 2018 May 17;3 (10) . pii: 120365.|[2]Grouix B, et al. PBI-4050 Reduces Stellate Cell Activation and Liver Fibrosis through Modulation of Intracellular ATP Levels and the Liver Kinase B1/AMP-Activated Protein Kinase/Mammalian Target of Rapamycin Pathway. J Pharmacol Exp Ther. 2018 Oct;367 (1) :71-81.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
ADC-L-103 Each
2,5-Dioxopyrrolidin-1-yl 3-(2-(4-formylbenzamido)ethoxy)propanoate
Sign In for Pricing
View Details E45H12467-2 20 µg
CDC2L5 (CDK13) (NM_031267) Human Over-expression Lysate
Sign In for Pricing
View Details 
BNC882631-100 1x 100 µL
Gastrin (GAST/2631), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details